Inflamax introduces ePDAT for real-time PRO data collection

Article

New tablet facilitates and standardizes patient reported outcomes data collection.

Toronto, Ontario-Inflamax Research has introduced its electronic Patient Data Acquisition Tablet (ePDAT) which not only facilitates but standardizes patient reported outcomes (PRO) data collection across multi-center clinical trials.

The validated ePDAT system provides a graphical user interface via a touchscreen tablet computer designed to provide an improved user experience. The system was designed to enhance user experience, accuracy, and quality while ensuring compliance with FDA and EMA requirements for validated ePRO data collection tools. ePDAT is fully CFR21 part 11 compliant.

PRO data can be collected by on-screen questionnaires, visual analog scales (VAS), response time, coordination tasks, high-resolution image capture, and evaluator interview via video conferencing.

Software architecture allows patient data to be recorded in real-time via the tablet’s cellular wireless connection to the company’s secure database servers. Data is also stored locally on the tablet as backup. 

Recent Videos
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
© 2025 MJH Life Sciences

All rights reserved.